G protein-coupled receptors (GPCRs) are key targets for drug discovery, but designing protein agonists and antagonists has been challenging due to their nature as integral membrane proteins. A recent study published in Nature describes the de novo design of miniproteins that can bind to GPCRs.
The researchers used computational methods to design small proteins that target specific GPCRs, including the angiotensin II type 1 receptor (AT1R) and the parathyroid hormone 1 receptor (PTH1R). The miniproteins were shown to bind with high affinity and specificity, and some acted as agonists or antagonists.
This approach could enable the development of new therapeutics for conditions such as hypertension and osteoporosis, though further research is needed to assess clinical potential. The study was led by scientists at the University of Washington and the Howard Hughes Medical Institute.
